Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$11.83 USD
-0.05 (-0.42%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $11.48 -0.35 (-2.96%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVTX 11.83 -0.05(-0.42%)
Will AVTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AVTX
Is AVTX preparing to trend higher? MACD Bullish Signal Line Cross shows up after slipping 0.42%
AVTX forms Pocket Pivot on September 19
Crossed Above 20 Day Moving Average appears for AVTX after 16.09% move
Oppenheimer Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX)
AVTX: HC Wainwright & Co. Raises Price Target and Maintains Buy Rating | AVTX Stock News